Semaglutide and tirzepatide are the most prescribed drugs in medicine. The weight loss story is well known. The cardiovascular and longevity evidence is more important and less understood.
The weight loss story is the story most physicians know. It is not the most important story.
GLP-1 receptor agonists were developed as antidiabetic agents. Their cardiovascular outcomes trials — required by the FDA following the rosiglitazone episode — produced some of the most striking cardiovascular mortality data seen in modern cardiology. The SELECT trial then demonstrated cardiovascular benefit in non-diabetic patients with obesity, which fundamentally changed the commercial and clinical profile of this drug class.
For physicians practicing longevity medicine, the question is not whether GLP-1 agonists reduce cardiovascular events in high-risk diabetic patients — that is now established. The question is what the evidence shows about aging biology, healthspan, and longevity-relevant endpoints in broader populations.
Five major cardiovascular outcomes trials have now reported for GLP-1 receptor agonists. The consistency of direction across trials in different populations, with different agents, is the foundation of the Strong evidence rating.
SELECT enrolled 17,604 non-diabetic adults with obesity (BMI ≥ 27) and established cardiovascular disease. Semaglutide 2.4mg weekly reduced the primary composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% (HR 0.80, 95% CI 0.72–0.90) over a mean follow-up of 39.8 months.
The SELECT result is significant for longevity medicine for two reasons. First, it demonstrates cardiovascular benefit independent of glycemic improvement — the mechanism operates through pathways beyond blood sugar control. Second, the trial population overlaps substantially with the preventive medicine patient — overweight, cardiovascular risk, but not yet diabetic.
What SELECT does not show: all-cause mortality benefit, longevity-specific endpoints, or benefit in populations without established cardiovascular disease. These questions are the subject of ongoing and planned trials.
GLP-1 receptor agonists have several mechanisms that are relevant to longevity biology beyond cardiovascular risk reduction. These include anti-inflammatory effects, reduction in visceral adiposity, improvements in metabolic flexibility, and emerging evidence of neurological protection.
Animal model data for GLP-1 agonists and lifespan extension exists but is limited and model-specific. The evidence for longevity-specific benefit in humans — as distinct from cardiovascular risk reduction — does not yet exist at the trial level. No published RCT has used longevity or healthspan as a primary endpoint for this drug class.
The honest position: GLP-1 agonists have Strong evidence for cardiovascular risk reduction in high-risk populations. The longevity-specific evidence is Emerging at best. Physicians prescribing this class for longevity purposes are extrapolating from cardiovascular outcomes data — which is a reasonable extrapolation but should be characterized as such to patients.
For physicians practicing longevity medicine, GLP-1 agonists occupy a unique position in the evidence hierarchy. They have the strongest cardiovascular outcomes evidence of any intervention in the longevity pharmacopeia. They also carry real side effect profiles — predominantly gastrointestinal — and real cost considerations.
The appropriate clinical framing is cardiovascular risk reduction with metabolic benefits — not longevity extension. The evidence supports the former clearly. The latter is a reasonable hypothesis awaiting trial evidence.